Global Information
회사소개 | 문의 | 비교리스트

세계의 항말라리아제 시장(2021-2028년)

Global Anti-malarial Drugs Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 1035387
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,230,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,832,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,439,000 PDF & Excel (Enterprise License)


세계의 항말라리아제 시장(2021-2028년) Global Anti-malarial Drugs Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 항말라리아제 시장은 신규 약제나 신규 병용요법의 연구가 활발해지면서 성장할 것으로 예측됩니다. 동남아시아의 말라리아 치료에서는 아르테미시닌이나 파트너 약제 내성에 대응하기 위해 아르테미시닌을 기반으로 한 3제 병용요법(TACT)이 개발되고 있습니다. 아프리카 국가에서는 현재 아르테미시닌 기반 병용요법(ACT)이 아직 유효하기 때문에 TACT는 약제 내성 위험을 경감하여 더 큰 커뮤니티와 향후 환자에게 이익을 가져옵니다. 이 어프로치는 혁신의 장벽을 간파하고, 그에 맞추어 정책적인 의미를 정의하기 위한 이행 연구에서 확립된 분석 툴이 되고 있습니다.

항말라리아제 대부분이 심각한 부작용을 수반하기 때문에 이러한 약의 수요가 감소할 것으로 예상됩니다. 예를 들면 하이드록시클로로퀸의 주요 부작용은 위장장애(구토, 설사, 위경련), 피부 발진, 두통, 현기증, 눈독성 등입니다. 그러나 부정맥, 기관지 경련, 혈관부종, 경련 등의 심각한 부작용이 보기 드물게 발생하는 경우가 있습니다. 이러한 요인이 시장 성장을 저해할 것으로 생각됩니다.

세계의 항말라리아제(Anti-malarial Drugs) 시장에 대해 조사했으며, 시장 개요와 함께 말라리아 종류별, 약제 클래스별, 유통 채널별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 세계의 항말라리아제 시장 - 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 세계의 항말라리아제 시장 - 시장 정의와 개요

제3장 세계의 항말라리아제 시장 - 주요 요약

  • 말라리아 종류별 시장 내역
  • 약제 클래스별 시장 내역
  • 유통 채널별 시장 내역
  • 지역별 시장 내역

제4장 세계의 항말라리아제 시장 - 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 항말라리아제 시장 - 업계 분석

  • Porter's Five Forces 분석
  • 역학 분석
  • 상환 분석
  • 미충족 수요

제6장 세계의 항말라리아제 시장 - COVID-19 분석

  • 시장에서의 COVID-19 분석
    • COVID-19 이전 시장 시나리오
    • COVID-19 현재 시장 시나리오
    • COVID-19 이후 또는 향후 시나리오
  • COVID-19의 가격 역학
  • 수요와 공급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 항말라리아제 시장 - 말라리아 종류별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 말라리아 종류별
    • 시장 매력 지수
  • 열대열 말라리아 원충
    • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 사일열 말라리아 원충
  • 삼일열 말라리아 원충
  • 난형 말라리아 원충
  • 원숭이 말라리아 원충

제8장 세계의 항말라리아제 시장 - 약제 클래스별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 약제 클래스별
    • 시장 매력 지수
  • 아미노퀴놀린
    • 클로로퀸
    • 하이드록시클로로퀸
    • 프리마퀸
    • 타페노퀸
    • 기타
    • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 퀴놀린-메탄올
    • 4-퀴놀린메탄올
    • 기타
  • 신코나 알칼로이드
    • 키니네(퀴닌)
    • 퀴니딘
  • 비구아니드
    • 프로구아닐
    • 클로로프로구아닐
  • 설폰아미드
    • 설파독신
    • 댑손
    • 기타
  • 설폰
  • 아르테미시닌 유도체
  • 기타

제9장 세계의 항말라리아제 시장 - 유통 채널별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 유통 채널별
    • 시장 매력 지수
  • 원내 약국
    • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 소매 약국
  • 온라인 약국

제10장 세계의 항말라리아제 시장 - 지역별

  • 서론
    • 시장 규모 분석, 백만 달러, 2019-2028년 및 전년대비 성장 분석(%), 2020-2028년, 지역별
    • 시장 매력 지수
  • 북미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 말라리아 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 약제 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 유통 채널별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 유럽
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 말라리아 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 약제 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 유통 채널별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 남미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 말라리아 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 약제 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 유통 채널별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 아시아태평양
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 말라리아 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 약제 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 유통 채널별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 중동과 아프리카
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 말라리아 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 약제 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 유통 채널별

제11장 세계의 항말라리아제 시장 - 경쟁 상황

  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마크
  • 주목해야 할 주요 기업 리스트
  • 파괴적 기술을 보유한 기업 리스트
  • 스타트업 기업 리스트

제12장 세계의 항말라리아제 시장 - 기업 개요

  • Ipca Laboratories Ltd.
    • 기업 개요
    • 제품 포트폴리오와 개요
    • 주요 하이라이트
    • 재무 개요
  • GlaxoSmithKline PLC
  • Cipla
  • Mylan N.V.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Alvizia Health Care

제13장 세계의 항말라리아제 시장 - DataM

  • 부록
  • 당사에 대해
  • 문의
KSM 21.11.16

Market Overview

Malaria is an infectious disease, which spreads through a bite of an infected female Anopheles mosquito, transferring parasites into the human body. Merozoites grow inside the red cells and destroy them, which further cause symptoms such as fever, tiredness, vomiting, and headache. The drugs that are used to treat and prevent malarial infections are called antimalarial.

The global anti-malarial drugs market size was valued US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

Market Dynamics

The market is predicted to grow due to increased research for novel medications and new combination therapies.

The different levels of the innovation system of antimalarial therapies in Nigeria and Burkina Faso are identified. The innovation systems approach explores the readiness of African countries for a transition to TACTs. The innovation systems approach assumes that integrating new technology in society is a collective effort in a complex social system. Triple artemisinin-based combination therapies (TACTs) are being developed to respond to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs can benefit the larger community and future patients by mitigating the risk of drug resistance. This approach has become a well-established analytical tool in transition studies to generate insight into innovation barriers and define policy implications accordingly.

Side effects associated with anti-malaria drugs are expected to hamper market growth.

Most anti-malarial drugs are associated with severe side effects, which is expected to decrease demand for these drugs. For instance, Hydroxychloroquine main side effects are gastrointestinal upset (vomiting, diarrhea, stomach cramps), skin rash, headache, dizziness, and ocular toxicity. However, serious side effects, including arrhythmia, bronchospasm, angioedema, and seizures, rarely occur. Such factors are expected to hamper market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has resulted in millions of infections, hundreds of thousands of deaths and major societal disruption due to lockdowns and other restrictions introduced to limit disease spread. Relatively little attention has been paid to understanding how the pandemic has affected malaria treatment, prevention, and control, which is a major cause of death and disease and predominantly affects people in less well-resourced settings. Malaria programs are being affected in many ways by COVID-19. To prevent malaria, insecticide-treated nets need regular renewal, but distribution campaigns have been delayed or canceled. For detection and treatment of malaria, individuals may stop attending health facilities out of fear of exposure to COVID-19 or because they cannot afford transport. Health care workers require additional resources to protect themselves from COVID-19. Supplies of diagnostics and drugs are being interrupted, compounded by the production of substandard and falsified medicines and diagnostics. These disruptions are predicted to double the number of young African children dying of malaria in the coming year and may impact efforts to control the spread of drug resistance. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Artemisinin Derivatives segment is expected to hold the largest market share in anti-malarial drugs market.

In 2020, the artemisinin derivatives segment accounted for the highest market share. Plasmodium falciparum parasites, the primary etiological agent of severe malaria, caused an estimated 229 million clinical cases and 409,000 deaths in 2019, predominantly in young African children. The disease is caused by the asexual blood stages, which complete their intra-erythrocytic developmental cycle (IDC) every 48 h. Globally, first-line treatment depends on artemisinin (ART)-based combination therapies (ACTs), which benefit from the exceptional potency of ART derivatives. The parasite activates these derivatives by hemoglobin-derived Fe2+-heme and kills rings and trophozoites via alkylation of proximal proteins, lipids, and heme. By combining two active ingredients with different mechanisms of action, ACTs are the most effective antimalarial medicines currently available in the market. For instance, the three standard ACTs (dihydroartemisinin-piperaquine, artesunate-mefloquine, and artemether-lumefantrine) and two TACTs containing partner drugs with opposing resistance mechanisms (dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine) for the treatment of malaria. However, the increasing consumption of artemisinin derivatives and monotherapies will boost the market in the forecast period.

Geographical Analysis

Middle East & Africa region holds the largest market share in the global anti-malarial drugs market

In 2020, the Middle East and Africa accounted for the highest revenue share. The region growth is attributed to the owing rapid surge in prevalence of malaria in the region. According to the World Health Organization, malaria is caused by five parasitic species, two of which - P. falciparum and P. vivax - are the most dangerous. The malaria parasite Plasmodium falciparum is the deadliest and most common on the African continent. In most places outside of Sub-Saharan Africa, P. vivax is the most common malaria parasite.

Moreover, the African region carries a disproportionately high share of the global malaria burden. In 2019, the region was home to 94% of all malaria cases and deaths. Nigeria (23 percent), the Democratic Republic of the Congo (11 percent), the United Republic of Tanzania (5 percent), Burkina Faso (4 percent), Mozambique (4 percent), and Niger (4 percent) accounted for over half of all malaria deaths globally (4 percent). Therefore, the above statements it has increased the demand for anti-malarial drugs. Thus, the Middle East and Africa region has led to the highest market share in the forecast period.

Competitive Landscape

Major key players in the anti-malarial drugs market are: GlaxoSmithKline PLC, Cipla, Mylan N.V., F. Hoffmann-La Roche AG, Novartis AG, Ipca Laboratories Ltd. and Alvizia Health Care. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of the anti-malarial drugs market globally. For instance, On February 4, 2021, Zydus Cadila announced that its antimalarial compound ZY19489 (MMV253) is in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has completed Phase I clinical evaluation [Reg'n Number ACTRN12619000127101]. In the first human study conducted in Australia, escalating doses of 25 to 1500 mg were administered to healthy human volunteers. A safety data review committee evaluated emerging pharmacokinetic (PK) and safety data.

Ipca Laboratories Limited:

Overview:

Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai, India. The company has been a crucial healthcare partner in over 120 countries across the 6 continents. It is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Moreover, the company is one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world's most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva. It has leading brands in Pain, Rheumatology, Antimalarials and Haircare therapy. Additionally, four formulations rank amongst the top 300 brands of IPM as per IQVIA.

Product Portfolio:

  • Brand - Cinkona
  • Generic - Quinine 150 mg / 5ml, Quinine 300 mg, Quinine 300 mg
  • Therapeutic Group - Malaria, Malaria, Malaria
  • Dosage Form - Suspension, Tablet, Injection

Why Purchase the Report?

  • Visualize the composition of the global anti-malarial drugs market segmentation by malaria type, drug class, distribution channel and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global anti-malarial drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global anti-malarial drugs market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global anti-malarial drugs market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Anti-malarial Drugs Market - By Malaria Type

  • Plasmodium falciparum
  • Plasmodium malariae
  • Plasmodium vivax
  • Plasmodium ovale
  • Plasmodium knowlesi

Global Anti-malarial Drugs Market - By Drug Class

  • Aminoquinolines
    • Chloroquine
    • HydroxyChloroquine
    • Primaquine
    • Tafenoquine
    • Others
  • Quinoline-methanol
    • 4-quinolinemethanols
    • Others
  • Cinchona Alkaloids
    • Quinine
    • Quinidine
    • Biguanides
    • Proguanil
    • Chlorproguanil
    • Sulfonamides
    • Sulfadoxine
    • Dapsone
    • Others
  • Sulfones
    • Artemisinin Derivatives
    • Others

Global Anti-malarial Drugs Market - By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Anti-malarial Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global Anti-malarial Drugs Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Anti-malarial Drugs Market - Market Definition and Overview

3. Global Anti-malarial Drugs Market - Executive Summary

  • 3.1. Market Snippet by Malaria Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Anti-malarial Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The market is predicted to grow due to increased research for novel medications and new combination therapies.
      • 4.1.1.2. Increasing awareness initiatives undertaken by the government are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with anti-malaria drugs are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Anti-malarial Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Reimbursement Analysis
  • 5.4. Unmet Needs

6. Global Anti-malarial Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Anti-malarial Drugs Market - By Malaria Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Malaria Type
    • 7.1.2. Market Attractiveness Index, By Malaria Type Segment
  • 7.2. Plasmodium falciparum*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Plasmodium malariae
  • 7.4. Plasmodium vivax
  • 7.5. Plasmodium ovale
  • 7.6. Plasmodium knowlesi

8. Global Anti-malarial Drugs Market - By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class Segment
  • 8.2. Aminoquinolines*
    • 8.2.1. Chloroquine
    • 8.2.2. HydroxyChloroquine
    • 8.2.3. Primaquine
    • 8.2.4. Tafenoquine
    • 8.2.5. Others
    • 8.2.6. Introduction
    • 8.2.7. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Quinoline-methanol
    • 8.3.1. 4-quinolinemethanols
    • 8.3.2. Others
  • 8.4. Cinchona Alkaloids
    • 8.4.1. Quinine
    • 8.4.2. Quinidine
  • 8.5. Biguanides
    • 8.5.1. Proguanil
    • 8.5.2. Chlorproguanil
  • 8.6. Sulfonamides
    • 8.6.1. Sulfadoxine
    • 8.6.2. Dapsone
    • 8.6.3. Others
  • 8.7. Sulfones
  • 8.8. Artemisinin Derivatives
  • 8.9. Others

9. Global Anti-malarial Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. Global Anti-malarial Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Malaria Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Malaria Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Malaria Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Malaria Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Malaria Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Anti-malarial Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Global Anti-malarial Drugs Market- Company Profiles

  • 12.1. Ipca Laboratories Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline PLC
  • 12.3. Cipla
  • 12.4. Mylan N.V.
  • 12.5. F. Hoffmann-La Roche AG
  • 12.6. Novartis AG
  • 12.7. Alvizia Health Care (*LIST NOT EXHAUSTIVE)

13. Global Anti-malarial Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us
  • 13.3. Contact Us
Back to Top
전화 문의
F A Q